Boston Scientific Corporation (NYSE:BSX) traded at $43.71 at last check on Monday, May 03, made an upward move of 0.25% on its previous day’s price.
Looking at the stock we see that its previous close was $43.6 and the beta (5Y monthly) reads 0.89. The company has a trailing 12-month PE ratio of 313.67. In terms of its 52-week price range, BSX has a high of $44.63 and a low of $32.99. The company’s stock has gained about 12.81% over that past 30 days.
Boston Scientific Corporation has a market cap of $62.64 Billion and is expected to release its quarterly earnings report on Jul 27, 2021- Aug 02, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the BSX stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0.37, with the EPS growth for the year raised at $1.58 for 2021 and $1.85 for next year. These figures represent 0.65% and 0.17% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $2.93 Billion, with a low of $2.69 Billion and a high of $2.97 Billion. The median projection represents growth adding up to 46.2% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $11.73 Billion, or +18.3% up from figures reported last year.
There have been 22 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the BSX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 29 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the Boston Scientific Corporation (BSX) stock as a Hold, while 22 rate it as a Buy. 2 analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the BSX stock currently stands at 27.1, and the most recent price level today is 6.44% off its SMA20 and 10.23% from its 50-day simple moving average. The RSI (14) is pointing at 73.22 while the volatility over the past week is 1.87% and drops to 1.75% over the past one month. The beta value is 0.89, while the average true range (ATR) is currently pointing at 0.85. The average price target for the stock over the next 12 months is $49.08, with the estimates having a low of $41 and a high of $52. These price ends are -6.2% and +18.97% off the today’s price level respectively, although investors could be excited at the prospect of a +14.39% if the BSX share price touches on the median price of $50.
Let’s briefly compare Boston Scientific Corporation (BSX) stock to its peers. We find that today’s price change of +0.25% and +16.33% over the past 12 months for BSX competes that of Abbott Laboratories (ABT), which has seen its stock price rise 0.02% in the latest trading session and is +30.39% over the last one year. Another of its peers Medtronic Inc (MDT) has climbed 0.53% today, and was +34.1% up over the past year, while Stryker Corp (SYK) is also up 0.25% yet, while its price remains in the green at 16.33% over the same period. Boston Scientific Corporation has a P/E ratio of 313.67 compared to Abbott Laboratorie’s 37.41 and Medtronic Inc’s 61.96. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.42% and 0.89%, respectively, in early deals.